Phase Forward shareholders OK sale
Shareholders holding a majority of Phase Forward shares voted on Tuesday to approve the transaction, which is still awaiting regulatory clearance.
Oracle plans to merge Waltham-based Phase Forward into its Health Sciences unit. The deal was disclosed in April.
Shares in Phase Forward fell 2 cents to $16.61 on the Nasdaq stock market. Oracle shares slid 21 cents to $22.68.